Overview
- Digemid ordered the immediate withdrawal and disposal of one Duoclamox lot and one Nitropruchyk lot after official tests found serious defects.
- Duoclamox 500 mg tablets in lot Z23-969 failed the clavulanic acid content test, which could weaken treatment for common infections.
- Nitropruchyk 50 mg injectable in lot 2124391A showed visible particles during safety checks, which can cause harm when given intravenously.
- Indecopi issued public alerts through its Consumer Alert System, urged people to stop using affected units, and shared the Digemid hotline at (01) 631-4300 for guidance or reports.
- Notices identify Zee Laboratories Ltd and Swiss Parenterals Ltd as the manufacturers and name Droguería Diphasac S.A.C. and Corporación H & K Pharma S.A.C. in Peru, with no confirmed clusters of adverse events or broad shortages reported so far.